Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Survey on hypersensitivity reactions associated with modified folfox-6 therapy for outpatients

  • At: 2008 FIP Congress in Basel (Switzerland)
  • Type: Poster
  • By: KIMURA, Masayuki (Department of Pharmacy Services, Saitama Med. Center, Saitama Med. University, Kawagoe, Saitama 350-8550, Japan)
  • Co-author(s): Sano, Motohiko (Department of Pharmacy Services, Saitama Med. Center, Saitama Med. University, KAWAGOE, SAITAMA 350-8550, Japan)
    Inoue, Naohiko (Department of Pharmacy Services, Saitama Med. Center, Saitama Med. University, KAWAGOE, SAITAMA 350-8550, Japan)
    Maruyama, Misaki (Outpatient Chemotherapy Division, Japan)
    Nakazawa, Takae (Outpatient Chemotherapy Division, Japan)
    Shimada, Hiromi (Outpatient Chemotherapy Division, Japan)
    Nagai, Fusako (Outpatient Chemotherapy Division, Japan)
    Okada, Norimichi (Department of Digestive Tract and General Surgery, Japan)
    Ishibashi, Keiichiro (Department of Digestive Tract and General Surgery, Japan)
    Ishida, Hideyuki (Department of Digestive Tract and General Surgery, Japan)
    Nakamura, Fusako (Department of Pharmacy,Satsukikai Ogasawara Clinic, Japan)
  • Abstract:

    OBJECTIVE:FOLFOX regimens including oxaliplatin (L-OHP) are widely used in patients with metastatic colorectal cancer in Japan. Hypersensitivity reactions (HRs) associated with L-OHP is one of the major adverse events in FOLFOX regimens. However, the incidence of HRs has not been fully clarified in Japanese patients. So, we tried to survey..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses